Imatinib mesylate polymorph and pharmaceutical composition thereof

A technology of imatinib mesylate and polymorphic form, which is used in drug combinations, antipyretics, anti-infectives, etc., can solve the problem of inability to ensure effective removal of mechanical impurities, unstable reproducibility, and poor product purity and other problems, to achieve the effect of suitable for industrial scale preparation, good stability and high purity

Active Publication Date: 2011-11-30
NANJING CAVENDISH BIO ENG TECH +1
View PDF6 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These existing methods have a series of shortcomings such as cumbersome process, unstable reproducibility, technical solutions that cannot ensure the effective removal of mecha

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Imatinib mesylate polymorph and pharmaceutical composition thereof
  • Imatinib mesylate polymorph and pharmaceutical composition thereof
  • Imatinib mesylate polymorph and pharmaceutical composition thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0115] The preparation of embodiment 1 imatinib mesylate crude product

[0116] Add imatinib (2Kg), methanesulfonic acid (390g) and acetone (20L) into the reaction flask, heat up to reflux for 2.5 hours under stirring. Cool down to room temperature, stir and crystallize for 3 hours. After suction filtration, the obtained filter cake was collected and dried under reduced pressure at 70°C to constant weight to obtain 2.2Kg of crude imatinib mesylate. Yield, 92.1%.

[0117] Purity: 98.7%.

Embodiment 2

[0118] The preparation of embodiment 2 polymorph II

[0119] Preparation of imatinib free base

[0120] The crude imatinib mesylate obtained in Example 1 (1.5 Kg) was added into water (15 L), heated to 60° C., and stirred to dissolve. Suction to remove impurities. The filtrate was cooled to room temperature, and acetone (4.5 L) was added with stirring. Sodium bicarbonate (214 g) was added and crystallized at room temperature for 3 hours. After suction filtration, the filter cake was washed with water and dried to constant weight to obtain 1.17Kg of imatinib. Yield: 92.9%.

[0121] Preparation of imatinib mesylate

[0122] The imatinib (1Kg) obtained above, methanesulfonic acid (195g) and methyl isobutyl ketone (10L) were added into the reaction flask, and the temperature was raised to reflux for 2 hours under stirring. Cool down to room temperature, stir and crystallize for 1 hour. After suction filtration, the obtained filter cake was collected and dried under reduced ...

Embodiment 3

[0126] The preparation of embodiment 3 polymorph II

[0127] According to the existing method, we used imatinib mesylate of different crystal forms prepared by different processes as raw materials, and adopted the scheme of Example 2 to prepare the data list of polymorph II as follows:

[0128]

[0129]

[0130] It can be seen from the above test data that the crude product of imatinib mesylate in any crystal form can be converted into the crystal form of the present invention. At the same time, impurities can be effectively removed to obtain high-purity imatinib mesylate up to 99.9%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a polymouphous substance II of imatinib mesylate, and also discloses a preparation method for the polymouphous substance and a medicinal composition of the polymouphous substance.

Description

technical field [0001] The present invention relates to a polymorphic form of a pharmaceutical compound, more specifically, to a polymorphic form of imatinib mesylate. In addition, the present invention also relates to a preparation method of the polymorphic form and a pharmaceutical composition thereof. Background technique [0002] Imatinib mesylate, a tyrosinase inhibitor, is used in the treatment of gastrointestinal stromal tumors (GISTs). Its chemical name is 4-(4-methylpiperazine-1-methyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidine-2-amino]phenyl]-benzene Formamide methanesulfonate, the chemical structure is as follows: [0003] [0004] Chinese patent application-Application No. 98807303.X (hereinafter referred to as Patent Application No. 303) discloses two polymorphs α and β of imatinib mesylate; wherein, the α crystal form is characterized by hygroscopicity, flow Needle crystal with poor properties, its typical XRPD pattern shows α-form at 4.9, 10.5, 14.9, 16.5,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D401/04A61K31/506A61P35/00A61P29/00A61P7/06A61P25/00A61P25/20A61P17/00A61P9/12A61P37/02A61P33/00A61P25/28
Inventor 严荣杨浩许永翔
Owner NANJING CAVENDISH BIO ENG TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap